To read the entire article and join the discussion please visit the following link: http://www.renewablesbiz.com/article/14/08/all-eyes-boston-will-new-commercial-food-waste-ban-lead-boom-waste-energy

EVEN YEHUDA, Israel, August 7, 2014 /PRNewswire/ —

Bluesphere Corp. (BLSP) (the “Company” or “Bluesphere”), a clean energy company that develops, manages and owns waste-to-energy projects, announced today a newly published report authored by three U.S. government agencies outlines new federal initiatives to support exponential growth in the private biogas waste-to-energy sector. The Biogas Opportunities Roadmap, published August 1st by the U.S. Department of Agriculture, U.S. Environmental Protection Agency, and U.S. Department of Energy concluded that:

Developing a viable biogas industry in the U.S. can boost the economy and provide a reliable, distributed source of renewable energy while reducing greenhouse gas emissions
2,000 biogas sites operate in the U.S. today, and more than 11,000 additional biogas systems could be deployed to handle organic waste and produce energy and biogas system co-products
Realizing the full potential of the biogas industry will require support from federal agencies, greater investment, expanded markets for biogas and biogas products, and increased R&D
The benefits of biogas systems are clear. The task ahead is to reduce barriers and promote financial opportunities to move forward in developing a robust biogas industry
In the Biogas Opportunities Roadmap, the federal agencies identify programs that will promote biogas utilization and help the private sector voluntarily realize the full potential of biogas systems. These programs include:

Using existing agency programs to leverage over $10 million in research funding
Fostering investments in biogas systems including reviewing government procurement programs for products of biogas systems
Strengthening markets for biogas systems and system products including by modernizing existing Federal incentives
Improving communication and coordination by establishing a Biogas Opportunities Roadmap Working Group that will include participation from DOE and EPA, as well as the dairy and biogas industries
“The potential for biogas to increase renewable energy production, reduce landfill waste, benefit the environment, and spur economic growth in the U.S. is significant. We are very pleased to see the U.S. government publish a report that outlines these benefits and opportunities. Bluesphere is actively working in several U.S. states to develop biogas facilities. We have brought our global expertise in building and operating waste-to-energy facilities to the U.S. market and we’re finding very strong interest in the value proposition we have to offer. We are eager to expand our operations in the U.S. in conjunction with some major partners and to capitalize on biogas opportunities,” stated Bluesphere CEO Shlomi Palas.

Bluesphere has begun design and engineering work, and is scheduled to break ground in 2014 on a 5.2 MW waste-to-energy anaerobic digester in Charlotte, North Carolina. The Company is also developing in a 3.2 MW waste-to-energy project in Rhode Island and has a Memorandum of Understanding to develop a 5.2 MW waste-to-energy project in Massachusetts.

JERUSALEM, August 19, 2014 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Intellectual Property Department of Spain has granted the Company’s patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins.”

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD[TM]) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). Having completed separate Phase IIa clinical trials, the company anticipates the initiation of separate Phase IIb clinical trials, in patients with both type 1 and type 2 diabetes under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition the company is developing an oral GLP-1 analog capsule (ORMD-0901).

For more information, the content of which is not part of this press release, please visithttp://www.oramed.com

Pompano Beach, Fla., Aug. 15, 2014 (GLOBE NEWSWIRE) — DS Healthcare Group, Inc. (DSKX), a leading developer of personal care products, today announced financial results for the three and six months ended June 30, 2014.

.

Net revenues were $3,744,000, up 9% over Q2 2013

.

Gross margins increase to 52% from 48% in Q2 2013

.

Gross profits increase to $1,942,000 up 21% over Q2 2013

.

Net loss narrows 16% to $(633,000) from Q2 2013

Net revenues were $3,744,434 for the three months ended June 30, 2014, an increase of 9.1% over revenues of $3,431,154 for the three months ended June 30, 2013. Revenue growth in the second quarter was driven by double-digit, year-over-year sales growth at the Company’s Mexican subsidiary, as well increased sell-through in foreign markets. Domestic sales declined in the quarter due to $1 million in backorders that were pending completion and shipment prior to the end of the quarter.

Gross margin increased to 51.9% in the second quarter of 2014 from 46.7% in the same quarter of the prior year as a result of improved production efficiencies, improved pricing from suppliers, and cost cutting efforts including reduced payroll. Gross profits were up 21% to $1,941,536 in the second quarter of 2014, as compared to $1,601,086 in the second quarter of 2013. Selling and marketing costs increased by 34% to $1,194,238 in the second quarter of 2014 from $894,366 in the same period last year. General and administrative costs declined by 2% to $1,338,536 in the three months ended June 30, 2014, as compared to $1,369,558 in the same period of 2013. DS Healthcare’s net loss narrowed by 16% to $(633,339) or $(0.04) per basic and diluted share in the second quarter of 2014 from $(757,063) or $(0.06) per basic and diluted share in the same period of 2013.

For the six months ended June 30, 2014 net revenues were $6,429,397, a 13% decline from revenues of $7,392,846 for the six months ended June 30, 2013. Net revenue growth at the Company’s Mexican subsidiary, as well increased sell-through in foreign markets was offset by a decline in domestic sales due to backorders that were pending completion and shipment.

Gross margin increased to 53.3% in the first half of 2014 from 45.7% in the first half of the prior year, as a result of improved production efficiencies, improved cost from suppliers, and cost cutting efforts including payroll. Gross profits were up 1.4% to $3,423,981 in the first half of 2014, as compared to $3,375,769 in the first half of 2013. Selling and marketing costs increased by 31% to $2,164,260 in the six months ended June 30, 2014 from $1,651,364 in the same period last year. General and administrative costs decreased by 7% to $2,672,480 in the first two quarters of 2014, as compared to $2,878,234 in the same period of 2013. DS Healthcare’s net loss increased by 22% to $(1,479,120) or $(0.09) per basic and diluted share in the first half of 2014 from $(1,215,056) or $(0.10) per basic and diluted share in the same period of 2013.

On June 30, 2014 the Company had cash and cash equivalents of $773,055 and working capital of $3,264,514. Total stockholders’ equity on June 30, 2014 was $4,852,418.

VIENNA, Va.–(BUSINESS WIRE)–

CEL-SCI Corporation (NYSE MKT:CVM) today announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) has added Centre Hospitalier Universitaire de Québec (CHUQ)’s L’Hotel Dieu de Quebec to its growing number of clinical sites in North America. CHUQ is a network of three teaching hospitals affiliated with the medical school of Université Laval and several specialized institutions in Quebec City. CEL-SCI plans to activate additional clinical sites for accelerated patient enrollment in Canada.

The Principal Investigator for CEL-SCI’s Phase III trial at CHUQ is Dr. André Fortin, a radiation oncologist and visiting professor. He is responsible for the research protocols of radiation therapy for the oncology group at CHUQ. Dr. Fortin has extensive expertise in the treatment of cancers using radiation therapy for head and neck, pulmonary, and digestive cancers. He is very involved in clinical research within the department as evidenced by his numerous publications.

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only. CEL-SCI’s Multikine investigational immunotherapy is intended to create an anti-tumor immune response to reduce local/regional tumor recurrence and thereby increase the survival rate of these patients.

“We are adding many additional centers in Canada and the U.S. for the world’s largest Phase III trial in head and neck cancer. This will hopefully keep us on schedule to complete global enrollment with approximately 880 patients by the end of 2015,” stated CEL-SCI Chief Executive Officer Geert Kersten.

About Multikine Phase III Study

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.